{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:56:52Z","timestamp":1794743812775,"version":"4.9.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Minufiya University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Quinazolinone derivatives have been broadly studied as anti-cancer drug candidates due to their potential to inhibit key signaling pathways involved in tumor progression. In the current study, new 2-[(4-substituted-5-methylfuran-3-yl)thio]-3-phenylquinazolin-4(3\n                    <jats:italic>H<\/jats:italic>\n                    )-one derivatives (\n                    <jats:bold>2<\/jats:bold>\n                    \u2013\n                    <jats:bold>10<\/jats:bold>\n                    ) were designed and assessed for anti-cancer activity. Cytotoxicity of the compounds was tested against normal WI-38 cells and cancer cell lines HepG-2 (liver), MCF-7 (breast), and HCT-116 (colorectal). In addition, their inhibitory effects on EGFR and VEGFR-2, key targets for tumor growth and angiogenesis, were assessed. Compounds\n                    <jats:bold>6b<\/jats:bold>\n                    and\n                    <jats:bold>10<\/jats:bold>\n                    showed significant cytotoxic activity, with\n                    <jats:bold>6b<\/jats:bold>\n                    (IC\u2085\u2080\u2009=\u20090.19\u2009\u00b1\u20090.03\u00a0\u03bcM) being the most effective EGFR inhibitor, over\n                    <jats:bold>10<\/jats:bold>\n                    (IC\u2085\u2080\u2009=\u20090.51\u2009\u00b1\u20090.04\u00a0\u03bcM) and as potent as erlotinib (IC\u2085\u2080\u2009=\u20090.23\u2009\u00b1\u20090.02\u00a0\u03bcM). Flow cytometry revealed that\n                    <jats:bold>6b<\/jats:bold>\n                    induced apoptosis in 35.29% of MCF-7 cells and G\u2082\/M phase cell cycle arrest, much better than that of untreated cells (6.81%). In silico ADMET prediction and molecular docking confirmed high EGFR binding affinity and favorable pharmacokinetic properties. Overall, compound\n                    <jats:bold>6b<\/jats:bold>\n                    showed promising anti-cancer activity via EGFR inhibition, apoptosis, and cell cycle arrest and is a good lead for further development as an EGFR-targeted agent.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-12140-1","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T18:04:54Z","timestamp":1753985094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Design, antiproliferative potency, and in silico studies of novel 5-methylfuran-3-yl)thio)-3-phenylquinazolin-4(3H)-one based derivatives as potential EGFR inhibitors"],"prefix":"10.1038","volume":"15","author":[{"given":"Sara M.","family":"Soliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel A.-H.","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman S.","family":"Nossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modather F.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Sabry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagar S.","family":"El-Hema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"4","key":"12140_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay, J.; Colombet, M.; Soerjomataram, I.; Parkin, D. M.; Pi\u00f1eros, M.; Znaor, A.; Bray, F. Cancer statistics for the year 2020: An overview.\u00a0Int. J. Cancer.\u00a0149(4), 778\u2013789 (2021).","journal-title":"Int. J. Cancer"},{"key":"12140_CR2","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1158\/2159-8290.CD-23-1160","volume":"13","author":"ACP Report","year":"2023","unstructured":"Report, A. C. P. & C. & Steering, C.,. Cancer in 2023. Cancer Discov. 13, 2510\u20132514 (2023).","journal-title":"Cancer Discov."},{"key":"12140_CR3","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/jnci\/djac158","volume":"114","author":"L Gallicchio","year":"2022","unstructured":"Gallicchio, L., Devasia, T. P., Tonorezos, E., Mollica, M. A. & Mariotto, A. Estimation of the number of individuals living with metastatic cancer in the United States. J. Natl. Cancer Inst. 114, 1476\u20131483 (2022).","journal-title":"J. Natl. Cancer Inst."},{"key":"12140_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s12032-022-01677-0","volume":"39","author":"P Sharma","year":"2022","unstructured":"Sharma, P., Jhawat, V., Mathur, P. & Dutt, R. Innovation in cancer therapeutics and regulatory perspectives. Med. Oncol. 39, 76 (2022).","journal-title":"Med. Oncol."},{"key":"12140_CR5","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1021\/cr9000226","volume":"109","author":"PD Eckford","year":"2009","unstructured":"Eckford, P. D. & Sharom, F. J. ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 109, 2989\u20133011 (2009).","journal-title":"Chem. Rev."},{"key":"12140_CR6","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1007\/s00018-008-8111-5","volume":"65","author":"H Lage","year":"2008","unstructured":"Lage, H. An overview of cancer multidrug resistance: A still unsolved problem. Cell. Mol. Life Sci. 65, 3145\u20133167 (2008).","journal-title":"Cell. Mol. Life Sci."},{"issue":"Suppl. 1","key":"12140_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000086183","volume":"14","author":"YA Luqmani","year":"2005","unstructured":"Luqmani, Y. A. Mechanisms of drug resistance in cancer chemotherapy. Med. Princ. Pract. 14(Suppl. 1), 35\u201348 (2005).","journal-title":"Med. Princ. Pract."},{"key":"12140_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szak\u00e1cs","year":"2006","unstructured":"Szak\u00e1cs, G. et al. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219\u2013234 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"12140_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25004\/IJPSDR.2012.040101","volume":"4","author":"MR Chorawala","year":"2012","unstructured":"Chorawala, M. R., Oza, P. M. & Shah, G. B. Mechanisms of anticancer drugs resistance: An overview. Int. J. Pharm. Sci. Drug Res. 4, 1\u20139 (2012).","journal-title":"Int. J. Pharm. Sci. Drug Res."},{"key":"12140_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ab.2004.11.015","volume":"338","author":"H Chen","year":"2005","unstructured":"Chen, H. et al. A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Anal. Biochem. 338, 136\u2013142 (2005).","journal-title":"Anal. Biochem."},{"key":"12140_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20503121211034366","volume":"9","author":"DT Debela","year":"2021","unstructured":"Debela, D. T. et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 9, 1\u201310 (2021).","journal-title":"SAGE Open Med."},{"key":"12140_CR12","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita Jr","year":"2008","unstructured":"DeVita, V. T. Jr. & Chu, E. A. History of cancer chemotherapy. Cancer Res. 68, 8643\u20138653 (2008).","journal-title":"Cancer Res."},{"key":"12140_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2018.00245","volume":"9","author":"K Nurgali","year":"2018","unstructured":"Nurgali, K., Jagoe, R. T. & Abalo, R. Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?. Front. Pharmacol. 9, 1\u201310 (2018).","journal-title":"Front. Pharmacol."},{"key":"12140_CR14","doi-asserted-by":"publisher","first-page":"106425","DOI":"10.1016\/j.bioorg.2023.106425","volume":"133","author":"XJ Liu","year":"2023","unstructured":"Liu, X. J. et al. Recent development of multi-target VEGFR-2 inhibitors for cancer therapy. Bioorg. Chem. 133, 106425 (2023).","journal-title":"Bioorg. Chem."},{"key":"12140_CR15","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.3390\/molecules27175688","volume":"27","author":"WA El-Sayed","year":"2022","unstructured":"El-Sayed, W. A. et al. New 1,2,3-triazole-coumarin-glycoside hybrids and their 1,2,4-triazolyl thioglycoside analogs targeting mitochondria apoptotic pathway: Synthesis, anticancer activity and docking simulation. Molecules 27, 5688 (2022).","journal-title":"Molecules"},{"key":"12140_CR16","doi-asserted-by":"publisher","first-page":"136358","DOI":"10.1016\/j.molstruc.2023.136358","volume":"1294","author":"AF Kassem","year":"2023","unstructured":"Kassem, A. F. et al. Novel pyridine-thiazolidinone-triazole hybrid glycosides targeting EGFR and CDK-2: Design, synthesis, anticancer evaluation, and molecular docking simulation. J. Mol. Struct. 1294, 136358 (2023).","journal-title":"J. Mol. Struct."},{"key":"12140_CR17","doi-asserted-by":"publisher","first-page":"105964","DOI":"10.1016\/j.bioorg.2022.105964","volume":"127","author":"ZM Alamshany","year":"2022","unstructured":"Alamshany, Z. M. et al. New thiophene, thienopyridine and thiazoline-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents and multitargeting kinase inhibitors. Bioorg. Chem. 127, 105964 (2022).","journal-title":"Bioorg. Chem."},{"key":"12140_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc1360","volume":"4","author":"A Gschwind","year":"2004","unstructured":"Gschwind, A., Fischer, O. M. & Ullrich, A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat. Rev. Cancer 4, 361\u2013370 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"12140_CR19","first-page":"291","volume":"3","author":"HH Popper","year":"2014","unstructured":"Popper, H. H., Ryska, A., Timar, J. & Olszewski, W. Molecular testing in lung cancer in the era of precision medicine. Transl. Lung Cancer Res. 3, 291\u2013300 (2014).","journal-title":"Transl. Lung Cancer Res."},{"key":"12140_CR20","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/fonc.2019.00800","volume":"9","author":"R Thomas","year":"2019","unstructured":"Thomas, R. & Weihua, Z. Rethink of EGFR in cancer with its kinase independent function on board. Front. Oncol. 9, 800 (2019).","journal-title":"Front. Oncol."},{"key":"12140_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1878-0261.12155","volume":"12","author":"S Sigismund","year":"2018","unstructured":"Sigismund, S., Avanzato, D. & Lanzetti, L. Emerging functions of the EGFR in cancer. Mol. Oncol. 12, 3\u201320 (2018).","journal-title":"Mol. Oncol."},{"key":"12140_CR22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1126\/science.8066447","volume":"265","author":"DW Fry","year":"1994","unstructured":"Fry, D. W. et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265, 1093\u20131095 (1994).","journal-title":"Science"},{"key":"12140_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature17960","volume":"534","author":"Y Jia","year":"2016","unstructured":"Jia, Y. et al. Overcoming EGFR T790M and EGFR C797S resistance with mutant-selective allosteric inhibitors. Nature 534, 129\u2013132 (2016).","journal-title":"Nature"},{"key":"12140_CR24","doi-asserted-by":"publisher","first-page":"133971","DOI":"10.1016\/j.molstruc.2022.133971","volume":"1270","author":"ES Nossier","year":"2022","unstructured":"Nossier, E. S. et al. Modified pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as EGFRWT and EGFRT790M inhibitors: Design, synthesis, and anti-cancer evaluation. J. Mol. Struct. 1270, 133971 (2022).","journal-title":"J. Mol. Struct."},{"key":"12140_CR25","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.3390\/molecules27206960","volume":"27","author":"HH Elganzory","year":"2022","unstructured":"Elganzory, H. H. et al. Design, synthesis, anticancer activity and molecular docking of new 1,2,3-triazole-based glycosides bearing 1,3,4-thiadiazolyl, indolyl and arylacetamide scaffolds. Molecules 27, 6960 (2022).","journal-title":"Molecules"},{"key":"12140_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4161\/mabs.2.2.11360","volume":"2","author":"LA Sullivan","year":"2010","unstructured":"Sullivan, L. A. & Brekken, R. A. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2, 2. https:\/\/doi.org\/10.4161\/mabs.2.2.11360 (2010).","journal-title":"MAbs"},{"key":"12140_CR27","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967\u2013974. https:\/\/doi.org\/10.1038\/nature04483 (2005).","journal-title":"Nature"},{"key":"12140_CR28","first-page":"15243","volume":"5","author":"WS El-Serwy","year":"2020","unstructured":"El-Serwy, W. S. et al. Thiopyrimidine-5-carbonitrile derivatives as VEGFR-2 inhibitors: Synthesis, anticancer evaluation, molecular docking, ADME predictions and QSAR studies. Chem. Sel. 5, 15243\u201315253 (2020).","journal-title":"Chem. Sel."},{"key":"12140_CR29","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ejmech.2014.07.071","volume":"84","author":"L Shi","year":"2014","unstructured":"Shi, L., Wu, T. T., Wang, Z., Xue, J. Y. & Xu, Y. G. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors. Eur. J. Med. Chem. 84, 698\u2013707. https:\/\/doi.org\/10.1016\/j.ejmech.2014.07.071 (2014).","journal-title":"Eur. J. Med. Chem."},{"key":"12140_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.lungcan.2006.02.009","volume":"53","author":"T Seto","year":"2006","unstructured":"Seto, T. et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 53, 91\u201396. https:\/\/doi.org\/10.1016\/j.lungcan.2006.02.009 (2006).","journal-title":"Lung Cancer"},{"key":"12140_CR31","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.humpath.2008.06.004","volume":"39","author":"S Ghosh","year":"2008","unstructured":"Ghosh, S. et al. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum. Pathol. 39, 1835\u20131843. https:\/\/doi.org\/10.1016\/j.humpath.2008.06.004 (2008).","journal-title":"Hum. Pathol."},{"key":"12140_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejca.2005.09.018","volume":"42","author":"SE Duff","year":"2006","unstructured":"Duff, S. E. et al. Vascular endothelial growth factors and receptors in colorectal cancer: Implications for anti-angiogenic therapy. Eur. J. Cancer 42, 112\u2013117. https:\/\/doi.org\/10.1016\/j.ejca.2005.09.018 (2006).","journal-title":"Eur. J. Cancer"},{"key":"12140_CR33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0022-5347(05)00736-6","volume":"175","author":"G Xia","year":"2006","unstructured":"Xia, G. et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J. Urol. 175, 1245\u20131252. https:\/\/doi.org\/10.1016\/S0022-5347(05)00736-6 (2006).","journal-title":"J. Urol."},{"key":"12140_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/jhet.4382","volume":"59","author":"SK Wahan","year":"2022","unstructured":"Wahan, S. K., Sharma, B. & Chawla, P. A. Medicinal perspective of quinazolinone derivatives: Recent developments and structure\u2013activity relationship studies. J. Heterocycl. Chem. 59, 239\u2013257 (2022).","journal-title":"J. Heterocycl. Chem."},{"key":"12140_CR35","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/1385272033486738","volume":"34","author":"A Witt","year":"2003","unstructured":"Witt, A. & Bergman, J. Recent developments in the field of quinazoline chemistry. Curr. Org. Chem. 34, 659\u2013677 (2003).","journal-title":"Curr. Org. Chem."},{"key":"12140_CR36","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1021\/acs.jmedchem.9b00656","volume":"62","author":"HP Buchstaller","year":"2019","unstructured":"Buchstaller, H. P. et al. Discovery and optimization of 2-arylquinazolin-4-ones into a potent and selective tankyrase inhibitor modulating Wnt pathway activity. J. Med. Chem. 62, 7897\u20137909 (2019).","journal-title":"J. Med. Chem."},{"key":"12140_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4103\/jrms.jrms_1025_21","volume":"27","author":"R Rezaeinasab","year":"2022","unstructured":"Rezaeinasab, R., Jafari, E. & Khodarahmi, G. Quinazolinone-based hybrids with diverse biological activities: A mini-review. J. Res. Med. Sci. 27, 68 (2022).","journal-title":"J. Res. Med. Sci."},{"key":"12140_CR38","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/molecules28030978","volume":"28","author":"AM Alsibaee","year":"2023","unstructured":"Alsibaee, A. M., Al-Yousef, H. M. & Al-Salem, H. S. Quinazolinones, the winning horse in drug discovery. Molecules 28, 978 (2023).","journal-title":"Molecules"},{"key":"12140_CR39","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3390\/molecules25061467","volume":"25","author":"R Teixeira","year":"2020","unstructured":"Teixeira, R. et al. Microwave-assisted synthesis of 4-phenylquinazolin-2(1H)-one derivatives that inhibit vasopressor tonus in rat thoracic aorta. Molecules 25, 1467 (2020).","journal-title":"Molecules"},{"key":"12140_CR40","doi-asserted-by":"publisher","first-page":"113778","DOI":"10.1016\/j.ejmech.2021.113778","volume":"225","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing. Eur. J. Med. Chem. 225, 113778 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"12140_CR41","doi-asserted-by":"publisher","first-page":"116137","DOI":"10.1016\/j.ejmech.2024.116137","volume":"266","author":"N Krasovska","year":"2024","unstructured":"Krasovska, N. et al. 5+1-Heterocyclization as preparative approach for carboxy-containing triazolo[1,5-c]quinazolines with anti-inflammatory activity. Eur. J. Med. Chem. 266, 116137 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"12140_CR42","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14756366.2020.1742117","volume":"35","author":"AS El-Azab","year":"2020","unstructured":"El-Azab, A.S.; Abdel-Aziz, A.A.-M.; Bua, S.; Nocentini, A.; AlSaif, N.A.; Alanazi, M.M.; El-Gendy, M.A.; Ahmed, H.E.A.; Supuran, C.T. S-substituted 2-mercaptoquinazolin-4 (3H)-one and 4-ethylbenzensulfonamides act as potent and selective human carbonic anhydrase IX and XII inhibitors. J. Enzyme Inhib. Med. Chem. 35, 733\u2013743 (2020).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"12140_CR43","doi-asserted-by":"publisher","first-page":"101866","DOI":"10.1016\/j.jsps.2023.101866","volume":"31","author":"AS El-Azab","year":"2023","unstructured":"El-Azab, A.S.; Abdel-Aziz, A.A.-M.; Bua, S.; Nocentini, A.; Bakheit, A.H.; Alkahtani, H.M.; Hefnawy, M.M.; Supuran, C.T.  Design, synthesis, and carbonic anhydrase inhibition activities of Schiff bases incorporating benzenesulfonamide scaffold: Molecular docking application. Saudi Pharm. J. 31, 101866 (2023).","journal-title":"Saudi Pharm. J."},{"key":"12140_CR44","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/14756366.2020.1722121","volume":"35","author":"AS El-Azab","year":"2020","unstructured":"El-Azab, A.S.; Abdel-Aziz, A.A.-M.; Ahmed, H.E.A.; Bua, S.; Nocentini, A.; AlSaif, N.A.; Obaidullah, A.J.; Hefnawy, M.M.; Supuran, C.T. Exploring structure-activity relationship of S-substituted 2-mercaptoquinazolin-4 (3H)-one including 4-ethylbenzenesulfonamides as human carbonic anhydrase inhibitors. J. Enzyme Inhib. Med. Chem. 35, 598\u2013609 (2020).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"12140_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/scipharm91020018","volume":"91","author":"MF Zayed","year":"2023","unstructured":"Zayed, M. F. Medicinal chemistry of quinazolines as anticancer agents targeting tyrosine kinases. Sci. Pharm. 91, 18 (2023).","journal-title":"Sci. Pharm."},{"key":"12140_CR46","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1039\/C7MD00097A","volume":"8","author":"I Shagufta","year":"2017","unstructured":"Shagufta, I. & Ahmad, A. An insight into the therapeutic potential of quinazoline derivatives as anticancer agents. Med. Chem. Comm. 8, 871\u2013885 (2017).","journal-title":"Med. Chem. Comm."},{"key":"12140_CR47","doi-asserted-by":"publisher","first-page":"13528","DOI":"10.1016\/j.heliyon.2023.e13528","volume":"9","author":"K Pedrood","year":"2023","unstructured":"Pedrood, K. et al. Design, synthesis, and cytotoxic evaluation of quinazoline derivatives bearing triazole-acetamides. Heliyon 9, 13528 (2023).","journal-title":"Heliyon"},{"key":"12140_CR48","doi-asserted-by":"publisher","first-page":"104982","DOI":"10.1016\/j.bioorg.2021.104982","volume":"113","author":"PSG Nunes","year":"2021","unstructured":"Nunes, P. S. G. et al. Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole-quinazolines as antiproliferative agents displaying ERK inhibitory activity. Bioorg. Chem. 113, 104982 (2021).","journal-title":"Bioorg. Chem."},{"key":"12140_CR49","doi-asserted-by":"publisher","first-page":"103814","DOI":"10.1016\/j.bioorg.2020.103814","volume":"9","author":"WY Huang","year":"2020","unstructured":"Huang, W. Y., Zhang, X. R., Lyu, L., Wang, S. Q. & Zhang, X. T. Pyridazino[1,6-b]quinazolinones as new anticancer scaffold: Synthesis, DNA intercalation, topoisomerase I inhibition and antitumor evaluation in vitro and in vivo. Bioorg. Chem. 9, 103814 (2020).","journal-title":"Bioorg. Chem."},{"key":"12140_CR50","doi-asserted-by":"publisher","first-page":"926","DOI":"10.2174\/1871520621666210524164351","volume":"22","author":"F Hakima","year":"2022","unstructured":"Hakima, F., Salfi, R., Bhikshapathi, D. & Khan, A. Anticancer evaluation of novel quinazolinone acetamides: Synthesis and characterization. Anti-Cancer. Agent. Me. 22, 926\u2013932 (2022).","journal-title":"Anti-Cancer. Agent. Me."},{"key":"12140_CR51","doi-asserted-by":"publisher","first-page":"24980","DOI":"10.1038\/s41598-024-73171-8","volume":"14","author":"AAH Abdel-Rahman","year":"2024","unstructured":"Abdel-Rahman, A. A. H. et al. Novel quinazolin-4-one based derivatives bearing 1,2,3-triazole and glycoside moieties as potential cytotoxic agents through dual EGFR and VEGFR-2 inhibitory activity. Sci. Rep. 14, 24980 (2024).","journal-title":"Sci. Rep."},{"key":"12140_CR52","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1021\/acs.jmedchem.6b01673","volume":"60","author":"PR Gilson","year":"2017","unstructured":"Gilson, P. R. et al. Optimization of 2-anilino 4-amino substituted quinazolines into potent antimalarial agents with oral in vivo activity. J. Med. Chem. 60, 1171\u20131188 (2017).","journal-title":"J. Med. Chem."},{"key":"12140_CR53","doi-asserted-by":"publisher","first-page":"111773","DOI":"10.1016\/j.ejmech.2019.111773","volume":"184","author":"K Haider","year":"2019","unstructured":"Haider, K. et al. Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review. Eur. J. Med. Chem. 184, 111773 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"12140_CR54","doi-asserted-by":"publisher","first-page":"103093","DOI":"10.1016\/j.bioorg.2019.103093","volume":"90","author":"KP Rakesh","year":"2019","unstructured":"Rakesh, K. P.; Kumara, H. K.; Ullas, B. J.; Shivakumara, J.; Gowda, D. C. Amino acids conjugated quinazolinone\u2013Schiff\u2019s bases as potential antimicrobial agents: Synthesis, SAR and molecular docking studies.  Bioorg. Chem. 90, 103093 (2019).","journal-title":"Bioorg. Chem."},{"key":"12140_CR55","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/scipharm90030052","volume":"90","author":"EM Mohi El-Deen","year":"2022","unstructured":"Mohi El-Deen, E. M., Nossier, E. S. & Karam, E. A. New quinazolin-4(3H)-one derivatives incorporating hydrazone and pyrazole scaffolds as antimicrobial agents targeting DNA gyrase enzyme. Sci. Pharm. 90, 52 (2022).","journal-title":"Sci. Pharm."},{"key":"12140_CR56","doi-asserted-by":"publisher","first-page":"112996","DOI":"10.1016\/j.ejmech.2020.112996","volume":"212","author":"S Malasala","year":"2021","unstructured":"Malasala, S. et al. Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug-resistant staphylococcus aureus and mycobacterium tuberculosis. Eur. J. Med. Chem. 212, 112996 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"12140_CR57","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ejmech.2015.03.014","volume":"94","author":"W Lu","year":"2015","unstructured":"Lu, W. et al. Synthesis, crystal structure and biological evaluation of substituted quinazolinone benzoates as novel antituberculosis agents targeting acetohydroxyacid synthase. Eur. J. Med. Chem. 94, 298\u2013305 (2015).","journal-title":"Eur. J. Med. Chem."},{"key":"12140_CR58","doi-asserted-by":"publisher","first-page":"115831","DOI":"10.1016\/j.ejmech.2023.115831","volume":"261","author":"S Zhou","year":"2023","unstructured":"Zhou, S. et al. Design, synthesis, and structure-activity relationships of a novel class of quinazoline derivatives as coronavirus inhibitors. Eur. J. Med. Chem. 261, 115831 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"12140_CR59","doi-asserted-by":"publisher","first-page":"112333","DOI":"10.1016\/j.ejmech.2020.112333","volume":"197","author":"AM Soliman","year":"2020","unstructured":"Soliman, A. M., Karam, H. M., Mekkawy, M. H. & Ghorab, M. M. Antioxidant activity of novel quinazolinones bearing sulfonamide: Potential radiomodulatory effects on liver tissues via NF-\u03baB\/PON1 pathway. Eur. J. Med. Chem. 197, 112333 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"12140_CR60","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature17960","volume":"534","author":"Y Jia","year":"2016","unstructured":"Jia, Y. et al. Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors. Nature 534, 129\u2013132 (2016).","journal-title":"Nature"},{"key":"12140_CR61","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.bmcl.2011.11.019","volume":"22","author":"PA Pl\u00e9","year":"2012","unstructured":"Pl\u00e9, P. A. et al. Discovery of AZD2932, a new quinazoline ether inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorg. Med. Chem. Lett. 22, 262\u2013266. https:\/\/doi.org\/10.1016\/j.bmcl.2011.11.019 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"12140_CR62","doi-asserted-by":"publisher","first-page":"202200189","DOI":"10.1002\/cbdv.202200189","volume":"19","author":"ZY Fang","year":"2022","unstructured":"Fang, Z. Y. et al. Design, synthesis and molecular docking of novel quinazolinone hydrazide derivatives as EGFR inhibitors. Chem. Biodivers. 19, 202200189 (2022).","journal-title":"Chem. Biodivers."},{"key":"12140_CR63","doi-asserted-by":"publisher","first-page":"104695","DOI":"10.1016\/j.bioorg.2021.104695","volume":"109","author":"AE Abdallah","year":"2021","unstructured":"Abdallah, A. E. et al. Design, synthesis and molecular modeling of new quinazolin-4(3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation. Bioorg. Chem. 109, 104695 (2021).","journal-title":"Bioorg. Chem."},{"key":"12140_CR64","doi-asserted-by":"publisher","first-page":"103422","DOI":"10.1016\/j.bioorg.2019.103422","volume":"94","author":"HA Mahdy","year":"2020","unstructured":"Mahdy, H. A. et al. Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Bioorg. Chem. 94, 103422 (2020).","journal-title":"Bioorg. Chem."},{"key":"12140_CR65","doi-asserted-by":"publisher","first-page":"107437","DOI":"10.1016\/j.bioorg.2024.107437","volume":"148","author":"NF El Hamaky","year":"2024","unstructured":"El Hamaky, N. F., Hamdi, A., Bayoumi, W. A., Elgazar, A. A. & Nasr, M. N. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study. Bioorg. Chem. 148, 107437 (2024).","journal-title":"Bioorg. Chem."},{"key":"12140_CR66","doi-asserted-by":"publisher","first-page":"26325","DOI":"10.1039\/D4RA04828H","volume":"14","author":"SS Tawfik","year":"2024","unstructured":"Tawfik, S. S. et al. S-Alkylated quinazolin-4(3H)-ones as dual EGFR\/VEGFR-2 kinase inhibitors: Design, synthesis, anticancer evaluation, and docking study. RSC Adv. 14, 26325\u201326339 (2024).","journal-title":"RSC Adv."},{"key":"12140_CR67","doi-asserted-by":"publisher","first-page":"131285","DOI":"10.1016\/j.molstruc.2021.131285","volume":"1247","author":"AA El-Sayed","year":"2022","unstructured":"El-Sayed, A. A., Nossier, E. S., Almehizia, A. A. & Amr, A. E. G. E. Design, synthesis, anticancer evaluation, and molecular docking study of novel 2,4-dichlorophenoxymethyl-based derivatives linked to nitrogenous heterocyclic ring systems as potential CDK-2 inhibitors. J. Mol. Struct. 1247, 131285 (2022).","journal-title":"J. Mol. Struct."},{"key":"12140_CR68","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/molecules25051096","volume":"25","author":"AEGE Amr","year":"2020","unstructured":"Amr, A. E. G. E. et al. Chiral pyridine-3,5-bis-(L-phenylalaninyl-L-leucinyl) Schiff base peptides as potential anticancer agents: Design, synthesis, and molecular docking studies targeting lactate dehydrogenase-A. Molecules 25, 1096 (2020).","journal-title":"Molecules"},{"key":"12140_CR69","doi-asserted-by":"publisher","first-page":"105504","DOI":"10.1016\/j.bioorg.2021.105504","volume":"119","author":"EA Abd El-Meguid","year":"2022","unstructured":"Abd El-Meguid, E. A., El-Deen, E. M. M., Moustafa, G. O., Awad, H. M. & Nossier, E. S. Synthesis, anticancer evaluation, and molecular docking of new benzothiazole scaffolds targeting FGFR-1. Bioorg. Chem. 119, 105504 (2022).","journal-title":"Bioorg. Chem."},{"key":"12140_CR70","doi-asserted-by":"publisher","first-page":"12889","DOI":"10.1039\/D3RA01931D","volume":"13","author":"ZM Alamshany","year":"2023","unstructured":"Alamshany, Z. M., Algamdi, E. M., Othman, I. M., Anwar, M. M. & Nossier, E. S. New pyrazolopyridine and pyrazolothiazole-based compounds as anti-proliferative agents targeting c-Met kinase inhibition: Design, synthesis, biological evaluation, and computational studies. RSC Adv. 13, 12889\u201312905 (2023).","journal-title":"RSC Adv."},{"key":"12140_CR71","doi-asserted-by":"publisher","first-page":"134130","DOI":"10.1016\/j.molstruc.2022.134130","volume":"1271","author":"AM Srour","year":"2023","unstructured":"Srour, A. M. et al. Design, synthesis, and molecular docking simulation of oxindole-based derivatives with dual VEGFR-2 and cholinesterase inhibitory activities. J. Mol. Struct. 1271, 134130 (2023).","journal-title":"J. Mol. Struct."},{"key":"12140_CR72","first-page":"451","volume":"88","author":"M Deshmukh","year":"2011","unstructured":"Deshmukh, M., Patil, S. S., Jadhav, S. & Mane, S. Y. Synthesis of some new 2-substituted quinazoline derivatives. J. Indian Chem. Soc. 88, 451\u2013455 (2011).","journal-title":"J. Indian Chem. Soc."},{"key":"12140_CR73","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.1002\/ejoc.201600975","volume":"30","author":"Y Peng","year":"2016","unstructured":"Peng, Y., Luo, J., Feng, Q. & Tang, Q. Understanding the scope of Feist-B\u00e9nary furan synthesis: Chemoselectivity and diastereoselectivity of the reaction between \u03b1-halo ketones and \u03b2-dicarbonyl compounds. Eur. J. Org. Chem. 30, 5169\u20135179 (2016).","journal-title":"Eur. J. Org. Chem."},{"key":"12140_CR74","doi-asserted-by":"publisher","unstructured":"Joule, J.A.; Mills, K. Heterocyclic chemistry. In: Comprehensive Heterocyclic Chemistry II, Vol. 2, 351\u2013393 (1996). https:\/\/doi.org\/10.1016\/B978-008096518-5.00046-0","DOI":"10.1016\/B978-008096518-5.00046-0"},{"key":"12140_CR75","doi-asserted-by":"publisher","first-page":"137790","DOI":"10.1016\/j.molstruc.2024.137790","volume":"1305","author":"RZ Batran","year":"2024","unstructured":"Batran, R. Z., Ahmed, E. Y., Nossier, E. S., Awad, H. M. & Latif, N. A. A. Anticancer activity of new triazolopyrimidine-linked coumarin and quinolone hybrids: Synthesis, molecular modeling, TrkA, PI3K\/AKT, and EGFR inhibition. J. Mol. Struct. 1305, 137790 (2024).","journal-title":"J. Mol. Struct."},{"key":"12140_CR76","doi-asserted-by":"publisher","first-page":"6321573","DOI":"10.1155\/2019\/6321573","volume":"2019","author":"IF Zeid","year":"2019","unstructured":"Zeid, I. F. et al. PI3K inhibitors of novel hydrazide analogues linked 2-pyridinyl quinazolone scaffold as anticancer agents. J. Chem. 2019, 6321573 (2019).","journal-title":"J. Chem."},{"key":"12140_CR77","doi-asserted-by":"publisher","first-page":"138741","DOI":"10.1016\/j.molstruc.2024.138741","volume":"1313","author":"AF Kassem","year":"2024","unstructured":"Kassem, A. F., Younis, A., Nossier, E. S., Awad, H. M. & El-Sayed, W. A. Pyridine-based glycosides bearing 1,2,4-triazole and their 1,3,4-oxadiazole analogues as potential EGFR and CDK-2 inhibitors: Design, synthesis, antiproliferative activity, and in silico studies. J. Mol. Struct. 1313, 138741 (2024).","journal-title":"J. Mol. Struct."},{"key":"12140_CR78","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1080\/17568919.2024.2431475","volume":"16","author":"AM Srour","year":"2024","unstructured":"Srour, A. M. et al. New pyrano-pyridine conjugates as potential anticancer agents: Design, synthesis, and computational studies. Future Med. Chem. 16, 2567\u20132582 (2024).","journal-title":"Future Med. Chem."},{"key":"12140_CR79","doi-asserted-by":"publisher","first-page":"13028","DOI":"10.1038\/s41598-024-62864-9","volume":"14","author":"HAS Abbas","year":"2024","unstructured":"Abbas, H. A. S., Nossier, E. S., El-Manawaty, M. A. & El-Bayaa, M. N. New sulfonamide-based glycosides incorporated 1,2,3-triazole as cytotoxic agents through VEGFR-2 and carbonic anhydrase inhibitory activity. Sci. Rep. 14, 13028 (2024).","journal-title":"Sci. Rep."},{"key":"12140_CR80","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/ijms19020448","volume":"19","author":"CM Pfeffer","year":"2018","unstructured":"Pfeffer, C. M. & Singh, A. T. K. Apoptosis: A target for anticancer therapy. Int. J. Mol. Sci. 19, 448 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"12140_CR81","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1039\/D5RA90011E","volume":"15","author":"AA Alsfouk","year":"2025","unstructured":"Alsfouk, A. A., Othman, I. M., Anwar, M. M., Saleh, A. & Nossier, E. S. Correction: Design, synthesis, and in silico studies of new quinazolinones tagged thiophene, thienopyrimidine, and thienopyridine scaffolds as antiproliferative agents with potential p38\u03b1 MAPK kinase inhibitory effects. RSC Adv. 15, 2758 (2025).","journal-title":"RSC Adv."},{"key":"12140_CR82","doi-asserted-by":"publisher","first-page":"138973","DOI":"10.1016\/j.molstruc.2024.138973","volume":"1316","author":"ZM Alamshany","year":"2024","unstructured":"Alamshany, Z. M. & Nossier, E. S. New thiazole derivatives linked to pyridine, fused pyridine, pyrimidine, and thiazolopyrimidine scaffolds with potential dual anticancer and antimicrobial activities: Design, synthesis, and docking simulation. J. Mol. Struct. 1316, 138973 (2024).","journal-title":"J. Mol. Struct."},{"key":"12140_CR83","doi-asserted-by":"publisher","first-page":"107471","DOI":"10.1016\/j.bioorg.2024.107471","volume":"149","author":"YS Sheta","year":"2024","unstructured":"Sheta, Y. S., Sarg, M. T., Abdulrahman, F. G., Nossier, E. S. & Husseiny, E. M. Novel imidazolone derivatives as potential dual inhibitors of checkpoint kinases 1 and 2: Design, synthesis, cytotoxicity evaluation, and mechanistic insights. Bioorg. Chem. 149, 107471 (2024).","journal-title":"Bioorg. Chem."},{"key":"12140_CR84","doi-asserted-by":"publisher","first-page":"15243","DOI":"10.1002\/slct.202002566","volume":"5","author":"WS El-Serwy","year":"2020","unstructured":"El-Serwy, W. S. et al. Thiopyrimidine-5-carbonitrile derivatives as VEGFR-2 inhibitors: Synthesis, anticancer evaluation, molecular docking, ADME predictions, and QSAR studies. ChemistrySelect 5, 15243\u201315253 (2020).","journal-title":"ChemistrySelect"},{"key":"12140_CR85","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1021\/ci200028n","volume":"51","author":"F Cheng","year":"2011","unstructured":"Cheng, F. et al. Classification of cytochrome P450 inhibitors and noninhibitors using combined classifiers. J. Chem. Inf. Model. 51, 996\u20131011. https:\/\/doi.org\/10.1021\/ci200028n (2011).","journal-title":"J. Chem. Inf. Model."},{"key":"12140_CR86","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3390\/molecules29051067","volume":"29","author":"ES Elsenbawy","year":"2024","unstructured":"Elsenbawy, E. S. et al. Designing potent anticancer agents: Synthesis and molecular docking studies of thieno[2,3-d][1,2,4]triazolo[1,5-a]pyrimidine derivatives. Molecules 29, 1067 (2024).","journal-title":"Molecules"},{"key":"12140_CR87","doi-asserted-by":"publisher","first-page":"133926","DOI":"10.1016\/j.molstruc.2022.133926","volume":"1270","author":"IM Othman","year":"2022","unstructured":"Othman, I. M. et al. Chemical synthesis and molecular docking study of new thiazole, thiophene, and thieno[2,3-d]pyrimidine derivatives as potential antiproliferative and antimicrobial agents. J. Mol. Struct. 1270, 133926 (2022).","journal-title":"J. Mol. Struct."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12140-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12140-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12140-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:59:13Z","timestamp":1757329153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12140-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12140"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12140-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27992"}}